Varian Calypso Anchored Beacon Transponder for Lung Receives FDA 510k Clearance

Friday, April 20, 2018 Respiratory Disease News
Email Print This Page Comment bookmark
Font : A-A+

PALO ALTO, Calif., April 20, 2018 /PRNewswire/ -- Varian (NYSE: VAR) today announced it has received FDA 510(k) clearance

for its Calypso® Anchored Beacon® transponder. Used with a Varian TrueBeam®, Edge® and Clinac® C-series medical linear accelerators, the Calypso system and Anchored Beacon transponder detects even
slight movements of a tumor and helps clinicians deliver lung stereotactic body radiotherapy (SBRT) more precisely.

The Calypso system works by implanting the Anchored Beacon transponders in small airways within or near the tumor target. The Anchored Beacon transponders feature five small "legs" that provide stable fixation to prevent the transponder from moving. The transponders emit non-ionizing electromagnetic signals that are tracked in real-time and used to keep a treatment beam on target.

The Calypso System is the only device on the market that delivers real-time, continuous (25 Hz update rate), 3D tumor position information, improving confidence that the prescribed dose has been delivered to the tumor.

"The 510(k) clearance of the Anchored Beacon transponder expands the application of the Calypso system platform," said Ed Vertatschitsch, vice president, Global Portfolio Solutions, Varian. "Using the Calypso system and Anchored Beacon transponder, clinicians can deliver dose to lung tumors with increased confidence and accuracy."

For more information on the Calypso system, visit www.varian.com/calypso.

About Varian Varian is a leader in developing and delivering cancer care solutions, and is focused on creating a world without fear of cancer. Headquartered in Palo Alto, California, Varian employs approximately 6,500 people around the world. For more information, visit http://www.varian.com and follow @VarianMedSys on Twitter.

Press Contact

Mark PlungyDirector, Public Relations+1 (650) 424-5630 mark.plungy@varian.com

Investor Relations Contact

J. Michael BruffSenior Vice President, Investor Relations+1 (650) 424-5163investors@varian.com

 

Cision View original content:http://www.prnewswire.com/news-releases/varian-calypso-anchored-beacon-transponder-for-lung-receives-fda-510k-clearance-300633354.html

SOURCE Varian



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store